TriangleNCT04145700 · OUTCOME
Pharmacokinetics (PK): Maximum Serum Concentration of Ramucirumab (Cmax)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- microgram per milliliter (µg/mL)
- Interval / dispersion
- Geometric Coefficient of Variation
- Time frame
- 0.5 hours after the end of ramucirumab infusion on Day 1 of Cycle 1
What was measured
Cmax was the concentration of study drug in the blood after the dose is administered. It was measured post-dose and was summarized using descriptive statistics.
Analysis population: All randomized participants who received at least one dose of Ramucirumab and had evaluable PK data.
Groups in this outcome
Ramucirumab + Gemcitabine + Docetaxel
Participants received intravenous infusions of ramucirumab 9 mg/kg, gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.
| Group | Source count |
|---|---|
| Ramucirumab + Gemcitabine + Docetaxel | 10 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ramucirumab + Gemcitabine + Docetaxel | 231 | 43 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 43
- value
- 231
- denoms
- counts
- group Id
- OG000
- value
- 10
- units
- Participants
- description
- Cmax was the concentration of study drug in the blood after the dose is administered. It was measured post-dose and was summarized using descriptive statistics.
- dispersion Type
- Geometric Coefficient of Variation
- groups
- description
- Participants received intravenous infusions of ramucirumab 9 mg/kg, gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.
- id
- OG000
- title
- Ramucirumab + Gemcitabine + Docetaxel
- param Type
- GEOMETRIC_MEAN
- population Description
- All randomized participants who received at least one dose of Ramucirumab and had evaluable PK data.
- reporting Status
- POSTED
- time Frame
- 0.5 hours after the end of ramucirumab infusion on Day 1 of Cycle 1
- title
- Pharmacokinetics (PK): Maximum Serum Concentration of Ramucirumab (Cmax)
- type
- SECONDARY
- unit Of Measure
- microgram per milliliter (µg/mL)
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice